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Limitations
We acknowledge the limitations of this study, with its
open-label treatment and retrospective analysis. However,
the sustained self-reported improvements, together with
partial waning of treatment at around 3 or 4 months in
many patients, as well as the long-term treatment and
follow-up in the majority of patients argue against pla-
cebo response being the only explanation for benefit.
Conclusions
Our data support the efficacy of BTX in the treat-
ment of proximal tremor. Functionally meaningful
improvements were observed in the majority of
patients, and these results should be verified with a
randomized, double-blind, placebo-controlled trial.
Legends to the Videos
Video Segment 1. This video demonstrates the
position-dependent upper limb proximal tremor with
internal-external rotatory component. Note that the
tremor is maximal with the hands held in the nose-
targeting position. The muscles injected were teres major
(20 units), teres minor (20 units), pectoralis major (20
units), supraspinatus (10 units), infraspinatus (10 units),
biceps (5 units). and triceps (5 units; total dose, 90 units).
Video Segment 2. This is a video clip of the same
patient in video segment 1, 5 weeks after botulinum
toxin injections.
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ABSTRACT
Background: We explored whether a noninvasive hand-
held device using Active Cancellation of Tremor (ACT)
technology could stabilize tremor-induced motion of a
spoon in individuals with essential tremor (ET).
Methods: Fifteen ET subjects (9 men, 6 women) per-
formed 3 tasks with the ACT device turned on and off.
Tremor severity was rated with the Fahn-Tolosa-Marin
Tremor Rating Scale (TRS). Subjective improvement
was rated by subjects with the Clinical Global Impres-
sion Scale (CGI-S). Tremor amplitude was measured
using device-embedded accelerometers in 11 subjects.
Results: TRS scores improved with ACT on (versus off) in
all 3 tasks: holding (1.006 0.76 vs. 0.276 0.70;
P5 0.016), eating (1.4761.06 vs. 0.136 0.64; P5 0.001),
and transferring (1.336 0.82 vs. 0.2760.59; P5 0.001).
CGI-S improved with eating and transferring, but not the
holding task. Accelerometer measurements demon-
strated 71% to 76% reduction in tremor with the ACT
device on.
Conclusions: This noninvasive handheld ACT device
can reduce tremor amplitude and severity for eating and
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transferring tasks in individuals with ET. VC 2013 Interna-
tional Parkinson and Movement Disorder Society
Key Words: essential tremor, treatment, noninvasive
device
Essential tremor (ET) causes upper limb action tremors
that may interfere with daily tasks such as eating.1 Medi-
cations for ET are variably effective and sometimes lim-
ited by side effects.2 Surgical treatments are effective but
typically reserved for more severe tremor.2,3 Improved
therapies are needed for individuals who do not respond
to medications but do not want to consider surgery.
We have developed a noninvasive handheld device
using Active Cancellation of Tremor (ACT) technology
to stabilize an eating utensil such as a spoon. The ACT
system senses tremor direction and moves the spoon
in the opposite direction to stabilize it (Supporting Fig.
1a). The device weighs about 100 g, with dimensions
similar to an electric toothbrush (40 3 50 3 175 mm).
Its rechargeable battery lasts for more than 90 minutes
of continuous use.
In this pilot study, we explored whether the ACT
device could stabilize a spoon held by ET subjects. We
hypothesized that the device would steady the spoon
during holding, eating, and transferring tasks.
Patients and Methods
Subjects
Consecutive subjects meeting diagnostic criteria for
ET4 with at least a “2” on the feeding or drinking
item of the Fahn-Tolosa-Marin Tremor Rating Scale
(TRS)5 were recruited from the University of Michigan
Movement Disorders Clinic. Subjects could have
undergone deep brain stimulation (DBS) surgery, but
had to meet inclusion criteria with the stimulation
turned off and have their stimulation turned off for
testing. The study was approved by the Institutional
Review Board for Human Research at the University
of Michigan.
ACT Prototype
The ACT device comprises 4 key subsystems: the
spoon, the motion-generating platform, the controller/
sensor, and the power supply. The spoon attaches to
the motion-generating platform and can be removed,
cleaned, or replaced. The motion-generating platform
uses 2 DC motors connected with mechanical yokes
that couple the vertical and horizontal motion of the
spoon. The sensor/controller subsystem uses a triaxial
accelerometer embedded in the spoon base to sense
the direction of tremor in the x (horizontal) and y
(vertical) directions (Supporting Fig. 1a) and directs
the motors to move the spoon in the opposite direc-
tion. Power is supplied by a rechargeable battery in
the handle. For this trial, the prototype was connected
to data acquisition hardware (100-Hz sampling rate,
12-bit accuracy) and a laptop computer running a
data acquisition program (written in LabView, version
2010; National Instruments Corporation, Austin, TX;
see Supporting Fig. 1b).
Clinical Testing
Overall tremor severity was evaluated in each sub-
ject using the TRS5 while off medication. The study
involved 3 tasks (holding, eating, and transferring
objects) with the ACT device using the dominant
hand, except in 2 subjects whose dominant hand
tremor was so severe with DBS turned off that the
ACT device was ineffective. The nondominant hand
was used for these 2 subjects.
For the holding task, subjects held the device mid-
way between the table and their mouth. We rated
tremor severity for the spoon tip, adapted from the
TRS upper limb tremor item. For the eating task, sub-
jects filled the spoon with foam blocks and lifted the
spoon to their lips. Tremor severity rating for this task
was adapted from the TRS feeding item. For the trans-
ferring task, subjects transferred a spoonful of foam
blocks into an empty cup 75 cm away. Tremor sever-
ity rating for this task was adapted from the TRS
pouring item.
Subjects performed each task at baseline with the
ACT device turned off while data and ratings were
recorded for 15-second durations. Subjects then per-
formed each task with the device turned on and off,
although the order was randomized. In these trials,
both subject and neurologist were blinded and not
told whether the device was turned on or off. After
each task, subjects rated the amount of improvement
using the Clinical Global Impression Scale (CGI-S).
This is a 7-point scale quantifying the subject’s
impression of whether his or her ability to perform
the task changed. Scoring was as follows: 15 very
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much improved, minimal symptoms; 25much
improved; 35minimally improved; 45no change;
55minimally worse; 65much worse; 75 very much
worse, severe exacerbation of symptoms.
Signal Processing
Accelerometer data in both directions of motion
cancellation (horizontal x and vertical y) were used to
determine tremor motion. Acceleration data as a func-
tion of time (Supporting Fig. 2a) were postprocessed
with a band-pass filter, resolving the signal into the
frequency domain using Fourier transformation. The
band-pass filter (first order, cutoff frequencies of 2 and
25 Hz) removed high-frequency noise. The filter also
attenuated low-frequency gravitational effects, assum-
ing that the patients’ intentional motion occurred well
below the 2-Hz cutoff frequency. Gravitational arti-
facts for more pronounced hand rotations may have
contributed to error on the horizontal axes. Although
this error is assumed to be small because the hand is
mostly horizontal, the acceleration signals serve as
estimates for the true segmental motion. The fast Fou-
rier transform (FFT) allows the dominant frequency of
vibration and magnitude of acceleration to be identi-
fied (Supporting Fig. 2b). Through double integration
of the acceleration at the dominant frequency with
respect to time, the amplitude of the tremor was deter-
mined. Overall magnitude of tremor motion was
determined by taking the Euclidean norm of the accel-
erometer readings in the 2 directions of motion cancel-
lation. The resulting accelerometer data are depicted
as a waveform by plotting acceleration against time
(Supporting Fig. 2a). This methodology was validated
in the vertical plane of motion using a high-speed
camera (120 fps) that recorded the vertical motion of
the spoon. Image processing (MATLAB, version
R2010a; MathWorks, Inc., Nattick, MA) yielded the
vertical absolute position over time, confirming the
vertical tremor amplitude determined from the
accelerometer.
Using the described signal extraction method, the
peak amplitude of the spoon’s displacement was then
recorded for each test. Although tremor frequencies
can vary across a range between 2 and 15 Hz, higher
tremor amplitudes correlate with lower frequencies.6
In the example shown in Supporting Figure 2b, the
peak amplitude of tremor occurred at 5 Hz.
Statistical Analysis
Changes in TRS score and CGI-S ratings for each
task with the ACT device turned on and off were
compared using the Mann-Whitney test. A P<0.05
was considered significant. The change in TRS item
for each task was calculated by taking the difference
of the TRS item from the blinded tests (device turned
on or off) and the baseline. For each of the 3 tasks,
the percentage of tremor reduction was extracted from
the postprocessed accelerometer data.
Results
Table 1 shows the baseline characteristics of the
15 subjects. Change in TRS scores significantly
improved on all 3 tasks with the device turned on
(Table 2). CGI-S scores improved significantly with
eating and transferring, but not holding (see Sup-
porting Video).
Eleven subjects (9 men, 2 women; mean age,
70.56 5.7 years; mean disease duration, 306 19
years) had accelerometer and video motion data that
could be analyzed; 4 subjects had excessive signal
noise discovered during postprocessing that prevented
their use. Accelerometer recordings of these 11 sub-
jects showed improvement in tremor amplitude for all
tasks (Table 3; Supporting Fig. 2a), including the
TABLE 1. Baseline characteristics of the cohort
Subject Age Sex
Dominant
hand
DBS
patient
Disease
duration (y)
Positive
family history
Medications at
time of testing
TRS feeding
score
TRS drinking
score
TRS total
score
1 59 F R N 40 Y Primidone 2 3 37
2 73 M R Y 32 Y Propranolol 3 3 47
3 69 M R Y 10 Y Propranolol, primidone 3 4 62
4 80 M R Y 65 Y Gabapentin 3 4 69
5 61 M R N 50 Y Atenolol 4 4 67
6 75 M R Y 17 Y Nadolol 3 3 38
7 78 F L N 5 N Primidone 3 2 36
8 66 M L N 15 N Propranolol, primidone 2 3 40
9 68 F L N 30 N Propranolol, topiramate 2 4 53
10 68 F R N 35 Y Propranolol, primidone 3 3 55
11 68 F R N 45 Y Propranolol, primidone 2 2 43
12 64 M L N 11 Y Primidone 1 3 22
13 72 M R Y 57 Y None 4 3 71
14 67 F R N 15 N Topiramate 2 3 41
15 79 M L N 8 Y Primidone, gabapentin 2 3 38
Mean (SD) 69.8 (6.3) 9 M/6 F 10 R/5 L 5 DBS 29 (19) 11 Y/4 N 2.6 (0.9) 3.1 (0.6) 47.9 (14.3)
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holding task. With the ACT device turned off, a strong
acceleration peak at the subject’s dominant tremor fre-
quency was noticed, which was greatly reduced with
the ACT device turned on (Supporting Fig. 2b).
Discussion
This small pilot study tested a noninvasive handheld
device using ACT technology to stabilize a spoon held
by ET subjects. The device significantly reduced spoon
tremor with the eating and transferring tasks based on
clinical ratings as well accelerometer data. Further-
more, subjects reported improved tremor with the eat-
ing and transferring tasks with the ACT device turned
on, using the CGI-S.
Subjects and the evaluating neurologist were not
told whether the device was on or off. The device pro-
totype also does not emit a sound or cause a palpable
sensation that can be detected by the user when turned
on. Despite this, true blinding may have been difficult
to achieve in a study like this. The potential to
unblind was greatest during the eating and transfer-
ring tasks because they used foam blocks to represent
food, which provided evidence of stabilization. How-
ever, with the device turned on, subjects did not notice
improvement in the holding task (based on CGI-S)
despite that both TRS and accelerometer measure-
ments showed considerable improvement. This sug-
gests that at least during this task, subjects were
blinded about whether the device was on or off.
There is a clear need for this type of noninvasive
device in managing tremor. Weighting the limb is a
commonly recommended noninvasive way to manage
limb tremor,7 but has little evidence to support it.8,9
Also investigated have been tremor suppression ortho-
ses,10-12 which function by physically forcing a per-
son’s tremor to cease.13 Because our device stabilizes
tremor while allowing the hand to shake, it has the
added benefits of being comfortable and easily
adopted by users.
There are other limitations to this small pilot study.
Two subjects had severe tremor amplitude with DBS
turned off, preventing use of our device, suggesting
that the device is most suitable for mild-moderate
tremors. We plan another trial to study the tremor
amplitude limit at which the ACT device is no longer
effective. In addition, only tremor while using a spoon
was evaluated. Improvement with eating was not dem-
onstrated, and the acceptability for long-term use
remains unknown.
Our results demonstrate the effectiveness of a nonin-
vasive handheld device using ACT technology to stabi-
lize a spoon. The device is lightweight and compact
and could potentially be outfitted with other tools,
such as a fork or mascara applicators. It has great
potential to help individuals accomplish tasks that
would otherwise be frustrating because of tremor.
TABLE 3. Tremor amplitude reduction based on accelerometer measurements
Subject
Tremor
amplitude
ACT off (cm)a
Tremor
amplitude
ACT off (cm)a
Tremor reduction (%)
Primary peak
frequency
ACT off (Hz)
Primary peak
frequency
ACT on (Hz)
Secondary
peak
frequency
ACT off (Hz)
Secondary
peak
frequency
ACT on (Hz)Combined Holding Eating Transferring
2 1.2 0.3 70% 77% 67% 66% 5.40 5.20 — —
3 1.6 0.2 82% 75% 90% 82% 5.90 5.30 — —
4 2 0.6 65% 63% 65% 67% 5.60 5.50 11.45 —
5 1 0.2 78% 84% 74% 77% 5.04 5.12 10.00 —
6 1.7 0.5 70% 56% 85% 69% 5.00 5.10 — —
8 1.9 0.4 77% 75% 79% 78% 5.87 5.60 — —
9 0.8 0.2 80% 77% 82% 82% 5.60 5.45 — —
10 1.7 0.6 72% 80% 74% 61% 5.40 4.80 — —
12 1.6 0.3 77% 81% 75% 76% 5.60 5.30 — —
13 0.5 0.2 41% 30% 50% 42% 4.20 4.40 — —
15 1.4 0.1 89% 90% 93% 85% 5.90 5.60 12.00 —
Mean 1.4 0.35 73% 72% 76% 71% 5.41 5.22 11.15 —
Standard
deviation
0.47 0.16 13% 17% 12% 12% 0.51 0.36 1.03 —
aTremor amplitude is the average amplitude of the subject during the 3 tasks. Frequency data are reported for the eating task.
TABLE 2. Clinical results with the Active Cancellation of
Tremor (ACT) device turned off and on.
n5 15
ACT off ACT on
PMean SD Mean SD
Change (DTRS) in holding 0.27 0.70 1.00 0.76 0.016a
Change (DTRS) in eating 0.13 0.64 1.47 1.06 0.001a
Change (DTRS) in
transferring
0.27 0.59 1.33 0.82 0.001a
Holding CGI-S 3.40 0.91 3.00 1.20 0.14
Eating CGI-S 4.00 0.66 2.13 1.41 0.000a
Transfer CGI-S 3.67 1.45 2.27 1.28 0.013a
TRS, Fahn-Tolosa-Marin Tremor Rating Scale. A positive change in TRS
indicates improvement in tremor.
aIndicates a P<0.05.
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Legend to the Video
This video demonstrates subjects using the device
during 3 tasks: holding, eating, and transferring, with
the device turned off and then on.
Acknowledgments: We thank Elizabeth Sullivan for her help in
coordinating the study visits.
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